<DOC>
	<DOCNO>NCT02177695</DOCNO>
	<brief_summary>The primary focus study see look tumor biomarkers use program call coexpression extrapolation `` COXEN '' may predict patient 's response chemotherapy surgery .</brief_summary>
	<brief_title>S1314 , Co-expression Extrapolation ( COXEN ) Program Predict Chemotherapy Response Patients With Bladder Cancer</brief_title>
	<detailed_description>The COXEN program select patient 's therapy , type chemotherapy he/she receive randomly decide . The patient 's response chemotherapy use test usefulness COXEN program , main goal trial . Other potential test predict patient 's response chemotherapy also evaluate . In study , patient may receive treatment Arm 1 ( gemcitabine cisplatin ) treatment Arm 2 [ methotrexate , vinblastine , doxorubicin , cisplatin , filgrastim ( pegfilgrastim ) ] . There 184 people take part study ( 92 arm ) .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically proven bladder cancer ( pure small cell carcinoma , pure adenocarcinoma , pure squamous cell carcinoma histology exclude ) . Stage cT2T4a N0 M0 disease . Documented muscle invasive disease least one following : disease measure least 10 mm crosssectional imaging OR presence tumorassociated hydronephrosis . Staging scan abdominal/pelvic CT MRI scan CT scan xray chest within 56 day prior registration . If alkaline phosphatase treat institution 's upper limit normal ( ULN ) , presence suspicious bone pain , clinical suspicion , whole body bone scan require within 56 day prior registration . Performance status = 0 1 18 year age old Must tumor tissue transurethral resection bladder tumor ( TURBT ) available submission sufficient COXEN testing must agree submission 20 ( 10 micron ) slide plus 2 ( 5 micron ) slide start end 20 slide total 22 unstained slide . Must agree collection tissue ( residual disease present ) , urine , whole blood . Must agree participate translational medicine study outline protocol Prior systemic cytotoxic chemotherapy systemic anthracycline Peripheral neuropathy &gt; /= Grade 2 Class III/IV heart failure know leave ventricular ejection fraction ( LVEF ) &lt; 50 % Clinically relevant hearing impairment &gt; Grade 2 Renal function , calculate creatinine clearance &lt; 60 mL/min Hepatic function , total bilirubin &gt; 1.5 x institutional upper limit normal ( IULN ) ( &gt; 2.5 x IULN Gilbert 's disease ) ; AST &amp; ALT &gt; 2 X IULN Hematologic function , absolute neutrophil count ( ANC ) &lt; 1,500/mcL , hemoglobin &lt; 9 g/dL , platelet &lt; 100,000/mcL Hypersensitivity cisplatin , gemcitabine , doxorubicin , vinblastine , methotrexate , filgrastim/pegfilgrastim Incidence uncontrolled medical illness ( e.g . active cardiac symptom , active systemic infection , etc . ) Pregnant nursing females No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient disease free five year . However , patient localized prostate cancer follow active surveillance program eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>Neoadjuvant Chemotherapy</keyword>
	<keyword>Coexpression Extrapolation</keyword>
	<keyword>COXEN</keyword>
	<keyword>S1314</keyword>
	<keyword>SWOG</keyword>
</DOC>